{
  "_id": "a108f3718e75dea6969138d5ce233b58909e59ad6732d4c4f521f9dbc3f54b3c",
  "feed": "wall-street-journal",
  "title": "Business News: Merck Lifts Outlook After Sales Leap 14%",
  "text": "<p>The company said revenue for its cancer treatment Keytruda and for its human papilloma virus vaccines Gardasil and Gardasil 9 increased 20% and 15% in the period, respectively, boosted by growth in the U.S. and Chinese markets.</p><p>Excluding the impact of a stronger dollar, sales for Keytruda and Gardasil -- Merck's top-selling drug and vaccine -- jumped 26% and 20%, respectively.</p><p>However, U.S. sales for its Type 2 diabetes drug, known under the brands of Januvia and Janumet, fell 15% as generic competitors grew, the company said.</p><p>Given current levels of demand, Merck expects to end the year with worldwide sales between $58.5 billion and $59 billion, up to 21% growth year over year. The company's previous guidance topped out at $58.5 billion.</p><p>For the third quarter, Merck's net income came to $3.25 billion, or $1.28 a share, compared with $4.57 billion, or $1.80 a share, a year earlier. Stripping out one-time items, Merck said adjusted earnings were $1.78 a share. Analysts recently polled by FactSet expected adjusted per-share earnings of $1.85.</p><p>Merck's stock closed up 1.4% to $99.74 a share.</p>",
  "published": "2022-10-28T00:00:00.000Z",
  "tags": [
    {
      "id": "US58933Y1055",
      "nexusId": "10042334",
      "name": "Merck & Co., Inc.",
      "offsets": [
        {
          "start": 306,
          "end": 311
        },
        {
          "start": 925,
          "end": 930
        },
        {
          "start": 1057,
          "end": 1062
        },
        {
          "start": 15,
          "end": 20
        },
        {
          "start": 565,
          "end": 570
        },
        {
          "start": 772,
          "end": 777
        }
      ]
    }
  ]
}